Klaus Engel

Topics • Strategy

Slowly But Surely: Short-Interviews with Hans Wijers, Steven Sterin, Patrick Jany, Curt Espeland, Klaus Engel and Axel Heitmann

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Evonik Industries AG

Klaus Engel

Kullmann appointed Deputy Chairman of the Executive Board of Evonik

Evonik Begins Silicones Project in China

Evonik Plans DL-Methionine Plant in Singapore

Evonik Starts C4 Plants with New Technology

Chemical Players Expect Gains on Cheap Oil and Euro

A Restructured Evonik May Seek a Major Acquisition

Evonik Invests in German Production and R&D Base

Evonik Breaks Ground on New Organics Production Facility in Shanghai

Evonik Owners Expect IPO Decision in April

Slowly But Surely: Short-Interviews with Hans Wijers, Steven Sterin, Patrick Jany, Curt Espeland, Klaus Engel and Axel Heitmann

Top-Feature

Upcoming Virtual Events

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Navigating Uncertainty and Driving Innovation

Klaus Engel

Top-Feature

Upcoming Virtual Events

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Newsletter & e-edition